Chromium for Blood Sugar: What the Evidence Really Shows
Educational summary — not medical advice, and not a treatment claim. Chromium is not an established treatment for diabetes, weight, or cravings; if you manage blood sugar or take medication, talk to your clinician before starting it. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
For blood sugar, chromium's evidence is modest and mixed, and only really studied in people with diabetes — it is not an established treatment. The three big meta-analyses disagree: Suksomboon 2014 found a small HbA1c drop (~−0.55%), Yin 2015 found no significant HbA1c effect, and Costello 2016 concluded "limited effectiveness." Weight effect is ~0.5 kg of uncertain relevance (Onakpoya 2013), and the craving/binge data is post-hoc or tiny-pilot. Two cautions: rare high-dose renal case reports and diabetes-medication overlap.
Blood sugar: three meta-analyses, three answers
This is the heart of the honest picture. When you pool the randomized trials, the answer depends on which review you read — so here are all three, side by side. Note they all study people with diabetes; none of this transfers to blood-sugar "support" in healthy people.
| Meta-analysis | What it pooled | Finding | The honest read |
|---|---|---|---|
| Suksomboon 2014 PMID 24635480 | 25 RCTs in people with diabetes | HbA1c −0.55%, fasting glucose −1.15 mmol/L — the most favorable review | A small, statistically significant effect — but modest, and in diabetics only |
| Yin 2015 PMID 25971249 | RCTs, split by chromium form | No significant HbA1c effect pooled; fasting-glucose signal only for the yeast form | Contradicts the "chromium lowers HbA1c" story; any signal is form-dependent |
| Costello 2016 PMID 27261273 | Evidence review for glycemic control | "Limited effectiveness" — little rationale to routinely recommend | The skeptical anchor: even where effects appear, they're small and inconsistent |
Read together, the fair summary is: a small, inconsistent glycemic effect in some people with diabetes, and no established benefit for the general population. Chromium is not a substitute for diabetes treatment, and the disagreement between these reviews is itself the finding — if the effect were robust, they'd converge.
Why "blood sugar support" oversells it Marketing leans on the single most favorable review (Suksomboon 2014) and drops the other two. But Yin 2015 found no significant HbA1c effect, and Costello 2016 called it "limited." Honest framing keeps all three: modest, contested, diabetics-only — a structure/function mineral, not a glucose-control treatment.
Weight: about half a kilogram, "clinical relevance uncertain"
Chromium is heavily marketed for weight loss, but the pooled trial evidence is thin. A meta-analysis of randomized trials in people with overweight or obesity found an average weight difference of just −0.5 kg versus placebo — and the authors themselves called the clinical relevance uncertain (Onakpoya 2013). Half a kilogram is well within the noise of everyday weight fluctuation and isn't a reason to take chromium for weight. It is not a proven weight-loss aid.
Cravings and binge eating: post-hoc and tiny pilots — don't generalize
The "chromium curbs cravings" claim is the weakest link, and it's important to be precise about why:
- Cravings: the widely-cited finding comes from a trial in atypical depression whose primary outcome was null; a drop in carbohydrate craving showed up only in a post-hoc subgroup (Docherty 2005). Post-hoc subgroup results are hypothesis-generating, not evidence of an effect — and this one is routinely over-cited.
- Binge eating: two pilot studies tested chromium in binge-eating disorder, but each enrolled only about two dozen people and were built to check feasibility and safety, not to prove it works (Brownley 2013; Sala 2017). Tiny n, exploratory design — not a basis for a general claim.
So: no reliable evidence that chromium reduces cravings or treats binge eating in the general population. Treat the craving marketing as unsupported.
Who it's (maybe) reasonable for — and who should skip it
- People with diabetes, as an adjunct only — where the small, inconsistent glycemic signal was seen (Suksomboon 2014), alongside — never instead of — prescribed care, and with your clinician's input.
- Not for weight loss or cravings — the weight effect is ~0.5 kg of uncertain relevance (Onakpoya 2013) and the craving data is post-hoc/pilot (Docherty 2005).
- Not in the general, non-diabetic population for "blood sugar support" — there's no reliable benefit there.
- Skip or get medical advice first if you have kidney or liver disease, or take diabetes medication.
And whatever you decide, don't overpay: chromium is a cheap commodity, all forms absorb about the same, and every product is many times the ~35 mcg you need.
Frequently asked questions
Does chromium lower blood sugar?
Modestly and inconsistently, in people with diabetes only — and it's not an established treatment. Three meta-analyses disagree: a small HbA1c drop (Suksomboon 2014), no significant effect (Yin 2015), and "limited effectiveness" (Costello 2016).
Does it help weight loss?
Barely. The pooled effect was ~0.5 kg with "clinical relevance uncertain" (Onakpoya 2013). It's not a proven weight-loss aid.
Does it reduce cravings or binge eating?
The evidence is weak. Craving data comes from a post-hoc subgroup of a null depression trial (Docherty 2005), and binge-eating results are from tiny (~24-person) pilots (Brownley 2013; Sala 2017). Not a general-population claim.
Is chromium safe?
Generally well tolerated at label doses (no established Upper Limit), but there are rare case reports of kidney injury at high-dose picolinate (Wasser 1997; Cerulli 1998; Wani 2006). Be cautious with kidney/liver disease or diabetes medication.
Related
- Chromium: what it is & the three label myths
- Dosage guide — the ~35 mcg adequate intake vs the shelf
- Forms & absorption — why picolinate isn't better absorbed
- Best chromium — ranked by cost per serving (it's a commodity)
Sources
- Suksomboon N, et al. "Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes." J Clin Pharm Ther. 2014. PMID: 24635480
- Yin RV, Phung OJ. "Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus." Nutr J. 2015. PMID: 25971249
- Costello RB, et al. "Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness." Nutr Rev. 2016. PMID: 27261273
- Onakpoya I, et al. "Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials." Obes Rev. 2013. PMID: 23495911
- Docherty JP, et al. "A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression." J Psychiatr Pract. 2005. PMID: 16184071 (primary null; post-hoc craving subgroup).
- Brownley KA, et al. "A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder." J Psychosom Res. 2013. PMID: 23751236 (pilot, n≈24).
- Sala M, et al. "Chromium and glucose regulation substudy in binge eating disorder." J Diet Suppl. 2017. PMID: 27835050 (pilot, n≈24).
- Wasser WG, et al. "Chronic renal failure after ingestion of over-the-counter chromium picolinate." Ann Intern Med. 1997. PMID: 9054292
- Cerulli J, et al. "Chromium picolinate toxicity." Ann Pharmacother. 1998. PMID: 9562138
- Wani S, et al. "Chromium picolinate and renal injury (acute tubular necrosis)." Ann Pharmacother. 2006. PMID: 16492795
- Laschinsky N, et al. "Bioavailability of chromium(III)-supplements in rats and humans." Biometals. 2012. PMID: 22814636